BIG NEWS: @JNJNews just publicly confirmed it will not enforce its secondary bedaquiline patents in ANY of 134 low- and middle-income countries. That's HUGE. Full credit to Johnson & Johnson for this commitment. This is what we've been waiting for. jnj.com/johnson-johnson-conf…

Johnson & Johnson Confirms Intent Not to Enforce Patents for SIRTURO® (bedaquiline) for the...

Company continues to be focused on addressing perceived barriers to access and refocusing global efforts on the most-pressing barrier to access: underdiagnosis of the disease. Decision builds on a...

jnj.com

Sep 30, 2023 · 2:26 PM UTC

52
497
4,436